Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01457417 · ClinicalTrials.gov registry record · Phase 1
A Study of DKN-01 in Multiple Myeloma or Advanced Solid Tumors
A Phase 1 study, sponsored by Leap Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT01457417 is a Phase 1 study that has completed, run by Leap Therapeutics. The registered enrollment target is 32 participants.
The verdict
NCT01457417, a Phase 1 study, has completed, sponsored by Leap Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
The purpose of this trial is to characterize the safety and toxicity of DKN-01 by determining a maximum-tolerated dose and associated dose limiting toxicity. To evaluate the pharmacodynamic response in patients with cancer. To characterize the pharmacokinetic parameters of DKN-01 in cancer patients who are intolerant to standard/approved therapies.
Interventions
- DRUG DKN-01
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2012-01 |
| Est. Completion | 2013-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01457417
The ClinicalTrials.gov registry entry for NCT01457417 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Leap Therapeutics, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which DKN-01 is the first listed.
NCT01457417 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01457417 about?
NCT01457417 is a clinical study titled "A Study of DKN-01 in Multiple Myeloma or Advanced Solid Tumors". The purpose of this trial is to characterize the safety and toxicity of DKN-01 by determining a maximum-tolerated dose and associated dose limiting toxicity. To evaluate the pharmacodynamic response in patients with cancer. To characterize the pharmacokinetic parameters of DKN-01 in cancer patients ...
What is the current status of trial NCT01457417?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2012-01. Estimated completion is 2013-12.
What interventions are being tested in trial NCT01457417?
The interventions under investigation include: DKN-01 (DRUG).
Who is sponsoring clinical trial NCT01457417?
This trial is sponsored by Leap Therapeutics, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.